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Background Tuberculosis is curable, but community surveys documenting epidemiological
impact of the WHO-recommended DOTS strategy on tuberculosis prevalence
have not been published. We used active community surveillance to compare
the impact of DOTS with earlier programmes.
Methods We conducted tuberculosis disease surveys using random cluster sampling of a
rural population in South India approximately every 2.5 years from 1968 to
1986, using radiography as a screening tool for sputum examination. In 1999,
DOTS was implemented in the area. Prevalence surveys using radiography and
symptom screening were conducted at the start of DOTS implementation and
after 2.5 years.
Results From 1968 to 1999, culture-positive and smear-positive tuberculosis declined by
2.3 and 2.5% per annum compared with 11.9 and 5.6% after DOTS
implementation. The 2.5 year period of DOTS implementation accounted for
one-fourth of the decline in prevalence of culture-positive tuberculosis over 33
years. Multivariate analysis showed that prevalence of culture-positive tuber-
culosis decreased substantially (10.0% per annum, 95% CI: 2.8–16.6%) owing
to DOTS after only slight declines related to temporal trends (2.1% annual
decline, 95% CI: 1.1–3.2%) and short-course chemotherapy (1.5% annual
decline, 95% CI: 9.7% to 11.5%). Under DOTS, the proportion of total cases
identified through clinical care increased from 81 to 92%.
Conclusions Following DOTS implementation, prevalence of culture-positive tuberculosis
decreased rapidly following a gradual decline for the previous 30 years. In the
absence of a large HIV epidemic and with relatively low levels of rifampicin
resistance, DOTS was associated with rapid reduction of tuberculosis prevalence.
Keywords Community surveys, mass chest X-ray, epidemiology, rifampicin, disease control,
tuberculosis, DOTS
Tuberculosis remains one of the leading infectious causes of
death globally, killing nearly 2 million people a year.
1
Tuberculosis control programmes can achieve a high level of
treatment success
1
and are associated with a decline in reported
disease burden.
2–5
However, there have been very few analyses
that included active, population-based surveillance of disease
burden before and after implementation of effective tubercu-
losis control measures and none published, of which we are
aware, that specifically evaluated the impact of the
WHO-recommended DOTS (Directly Observed Treatment,
Short-course) strategy.
In India, DOTS has been implemented as the Revised
National Tuberculosis Control Programme (RNTCP) since
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1993. The RNTCP expanded rapidly throughout India starting
in 1998, with essentially the entire country covered in 2006.
6
Diagnosis is primarily by sputum microscopy. Treatment is
standardized and thrice-weekly throughout, with every dose to
be directly observed in the initial phase and at least one dose
per week to be directly observed in the continuation phase.
Medicines are supplied in boxes each containing a full course of
treatment for an individual patient. Standardized methods of
recording and reporting are used. Policy direction, drugs, and
equipment are provided by the central government, with
state governments responsible for programme staffing and
implementation.
7
The Tiruvallur area of India provides a unique opportunity to
evaluate the rate of tuberculosis prior to and after imple-
mentation of DOTS. In 1968, a 15 year Bacillus Calmette-
Guerin (BCG) vaccine trial was begun in the area
8
; disease
burden in the population was monitored intensively and
rigorously through active surveys in the community over the
ensuing 15 years. In 1985, short-course chemotherapy with
rifampicin-containing regimens was introduced in the area, but
without direct observation of treatment or the management
interventions of the DOTS strategy. In 1999, a new interven-
tion study was begun based on the DOTS strategy. A baseline
survey of disease prevalence among adults was conducted at
the start of the DOTS programme and a follow-up survey was
conducted after 2.5 years. In all, this analysis represents more
than 700 000 mobile X-ray evaluations, most in remote rural
areas, and sputum examinations of 40 000 people.
Methods
Sampling
Cases were identified both through presentation at clinics and
active community survey. Clinically diagnosed, culture-
negative cases were not included in the analyses as there is
no gold standard for diagnosis of culture-negative tuberculosis
and the great majority of tuberculosis cases are culture-positive.
Surveys took 2.5 years. Of ~500 000 people in 218 clusters
representing the sampling unit (209 villages and 9 towns) in
five different areas, or blocks, each survey between 1968 and
1986 randomly selected 78 clusters (74 villages, 4 towns), and
every adult in these areas formed the survey population. For
the two surveys between 1999 and 2003 (DOTS period),
53 clusters (50 villages and 3 towns) were selected at random
from the 78 surveyed earlier. The total population covered was
83 431 and 84 572 for these two surveys, and population within
each cluster ranged from 516 to 5429 for the first survey and
476 to 5649 for the second survey. Thus, there were three
periods: prior to use of rifampicin-containing, short-course
chemotherapy regimens (pre-SCC, 1968–1986); after intro-
duction of rifampicin-containing regimens (SCC, 1986–1999);
and during DOTS implementation (DOTS, 1999–2003). The
pre-SCC and SCC periods constitute the pre-DOTS phase of
tuberculosis treatment services in this area.
Survey methodology
Survey methods have been described in detail elsewhere.
8–10
All persons in the selected villages/towns were registered by
door-to-door census, and adults aged >15 years present at
the time were questioned regarding chest symptoms and
underwent a chest radiograph (70 mm photofluorogram,
postero-anterior view) at a nearby health centre. This
radiograph was read independently by two readers and,
in case of disagreement, by a third reader. In the community
survey, we evaluated both those with radiographic abnormal-
ities suggestive of tuberculosis and those who presented at
health facilities in the survey area with symptoms suggestive of
tuberculosis who had an abnormal chest X-ray.
In the initial disease surveys, from 1968 to 1986, two sputum
specimens were collected from patients who had an abnormal
X-ray suggestive of tuberculosis. Sputum samples were sub-
jected to smear and culture examination, with specimens
yielding growth subjected to identification tests for Mycobac-
terium tuberculosis. If the smear result was positive for acid-fast
bacilli (AFB), one more sputum sample was collected. Patients
who had two positive smears, or who were culture-positive,
were considered to have tuberculosis and were referred to a
health facility for anti-tuberculosis treatment. If only one smear
was positive, action was taken based on radiographic results.
11
Patients were categorized and treated as per World Health
Organization guidelines.
12
Patients absent for examination
were revisited the same day or on subsequent days until at least
90% of patients had provided the required number of sputum
specimens.
9
Patients who did not commence treatment despite
being reminded by three home visits were considered initial
defaulters.
Surveys were repeated every 2.5 years. In the DOTS period
(1999–2003), in addition to chest radiography, survey parti-
cipants were asked about pulmonary symptoms (i.e. cough for
>2 weeks, chest pain or fever for 1 month or more, or
haemoptysis at any time during the previous 6 months); those
with either an abnormal radiograph suggestive of tuberculosis
or chest symptoms were asked to submit two sputum
specimens.
11
These were examined by fluorescence microscopy
and cultured on Lowenstein–Jensen medium.
Numbers and cases in study
For the primary analysis of trends in the prevalence of
tuberculosis and the impact of short-course chemotherapy
and DOTS, we have restricted the analysis to the cases identified
by radiographic screening alone (the number varied from
62 000 to 92 000) as this method was employed uniformly in all
the surveys (Table 1).
Case definitions
People with a positive culture for M. tuberculosis, regardless of
smear, were considered culture-positive cases. People with a
positive smear containing more than three acid-fast bacilli
(AFB), regardless of culture, were considered smear-positive
cases. The policy was to examine each slide for at least 5 min
before declaring it to be smear-negative for AFB.
Estimation of prevalence in the community
If Xi is the number of eligible persons in the ith subgroup (by
sex and by age), xi is the number assessed (by radiography), Si
is the number eligible for sputum collection (based on
abnormal radiograph), si is the number with a sputum
examination, and fi is the number with a positive finding
(culture/smear), the total number of positives in the ith
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subgroup is conventionally estimated as (fi/si) · (Si/xi) · Xi 5
Ci, assuming that the findings in those not examined would be
the same as in those assessed.
9
In this study, however, the number of sputum-positive cases
among those that did not have sputum collected was estimated
from the nature of the radiographic abnormality by utilizing
the probability of a positive finding in the appropriate
radiographic category
8,9
; within each category, it was higher
in those with chest symptoms than in those without. Thus,
eligible subjects who did not have a sputum examination (~4%
in the 1999–2001 survey) were classified into 16 categories
(4 by radiography · 2 by symptom status · 2 by sex), and the
number in each group was multiplied by the culture-positive
probability, to estimate the number of missed culture-positive
cases, and multiplied by the smear-positive probability, to
estimate the number of missed smear-positive cases.
9
To estimate the number of cases among those with no
radiograph, the relative risk (RR) of a person having chest
symptoms (compared with that of a person with a radiograph)
was taken as a proxy for the RR of a person without a
radiograph having tuberculosis (compared with a person with a
radiograph); this did not appear to be influenced by age and
was 0.6 for males and 0.4 for females.
8,9
The number of missed
cases owing to non-coverage by radiograph or sputum
examination was added to the observed number of cases,
and overall estimates of culture-positive and smear-positive
tuberculosis were obtained (for both sexes and all ages
combined) by pooling of appropriate categories.
9
Statistical analysis
A cluster sampling design was used for each survey. The
required sample size was estimated to be 82 000 adults aged
>15 years for precision of 20% at a 95% confidence level,
proportion examined (coverage) of 90%, and a design effect
of 2.
9
Statistical methods employed were the Chi-square test
for equality of proportions, linear regression analyses for
determining rate of decline over time, and standardization
by the direct method.
Prevalence was estimated for each survey and age–sex
standardized to the population of the 1968–1970 survey. A
weighted multivariate regression analysis of log prevalence on
time was undertaken, including rifampicin and DOTS as
dummy variables; the weight was the inverse of the sampling
variance of the prevalence estimate.
Ethical considerations
The institutional ethics committee of the Tuberculosis Research
Center, Indian Council of Medical Research, approved the
project.
Programme implementation and performance
During the pre-SCC period, the average proportion of the
estimated annual incident smear-positive cases detected and
treated in the programme was reported to be 30% of total
estimated new smear-positive cases, and only 30% of those
starting treatment completed treatment.
13
During the SCC
period, the detection rate increased slightly to ~45% of the
estimated total new smear-positive cases and treatment com-
pletion also increased to ~50%.
14
The government of Tamil
Nadu implemented the DOTS strategy in this area in May 1999.
In the pre-SCC period, non-rifampicin-based regimens
were used almost exclusively. In the SCC period, many
patients, particularly those who were AFB smear-positive,
received rifampicin-containing regimens but entirely under
Table 1 Prevalence of tuberculosis (per 100 000), standardized to 1968–1970 population, based on screening by radiography alone
(for population in five blocks in South India)
Examined by radio-
graphy in the survey
Sputum
examined Prevalence Standardized prevalence
a
Period of
survey
Sample
size No. % Abnormal No. % C1 rate
b
S1 rate
c
C1 rate
b
S1 rate
c
1968–1970 77 089 61 718 80 6646 6143 92 1017 630 1017 630
1971–1973 84 760 70 312 83 4264 3686 86 876 565 894 576
1973–1975 88 213 73 133 83 6115 5310 87 915 586 942 603
1976–1978 94 837 83 242 88 4673 4466 96 857 476 894 498
1979–1981 98 816 87 432 88 4132 3863 93 791 529 820 550
1981–1983 102 999 91 645 89 6237 5975 96 775 579 808 602
1984–1986 104 611 91 881 88 5445 5190 95 671 507 688 519
1999–2001 83 431 75 121 90 3355 3206 96 508 274 510 276
2001–2003 85 472 77 216 90 2768 2616 95 363 232 372 239
Annual decrease (%) in
Pre-SCC period (years 0–15) 2.3
(1.4 to 3.2)
d
0.9
(0.7 to 2.7)d
2.1
(1.1 to 3.2)
d
0.9
(0.7 to 2.3)d
SCC period, pre-DOTS (years 15–30) 1.8 4.1 2.1 4.1
DOTS programme (years 30–32.5) 12.5 6.5 11.9 5.6
a
Standardized with reference to 1968–1970 survey population.
b
Prevalence of culture-positive tuberculosis (per 100 000), smear either positive or negative.
c
Prevalence of smear-positive tuberculosis (per 100 000), culture either positive or negative.
d
Range in brackets denotes 95% CI.
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self-administration. In the DOTS period, nearly all patients
received rifampicin-containing, thrice weekly regimens, with
medication administration that was to be directly observed
thrice weekly (i.e. all doses) in the initial 2–4 month treatment
period and at least once per week in the follow-up treatment
period. National policies, treatment regimens, and results of
DOTS implementation have been described elsewhere.
7
Dia-
gnosis in clinical facilities was largely based on radiological
examination in the pre-SCC period, single AFB smear and
radiological examination in the SCC period, and three AFB
smears, if negative, followed by empiric antibiotic treatment
and then radiological examination in the DOTS period.
Results of DOTS implementation in the project are as follows.
Against an estimated 85 new smear-positive cases per 100 000
population, the average case detection rate between 1999 and
2003 was 86% in the study area (range 65–94%; WHO global
target >70%1). The average treatment success rate for new
smear-positive patients was 77% (range 71–80%; WHO global
target >85%1). Case detection in the project area is somewhat
higher, and treatment success somewhat lower, than in the rest
of the national programme.
7
Throughout the survey period, all
diagnosed cases were referred to the nearest governmental
health facility for further management. Patients were treated
on an ambulatory basis, with drugs supplied for self-
administration during pre-SCC and SCC periods. During the
DOTS period, directly observed treatment was given by either
governmental or community providers; attempts were made
to involve the private sector, and sensitization programmes
were conducted for the private sector, village officers, and the
community. Virtually all private practitioners, although only
a minority of private laboratories, participated and referred
patients with symptoms of tuberculosis. No enablers or
incentives were used at any time.
Results
During the pre-SCC period, there was a small decline of 2.1%
per annum in the prevalence of culture-positive tuberculosis
(95% CI: 1.1–3.2%), from 1017 per 100 000 in 1968–1970 to
688 per 100 000 in 1984–1986 (Table 1, Figure 1). The annual
rate of decline was the same in the SCC period, with prevalence
decreasing to 510 per 100 000 in 1999–2001, but the rate of
decline accelerated substantially after DOTS implementation to
11.9% per annum, with prevalence decreasing to 372 per
100 000 in 2001–2003.
Smear-positive tuberculosis prevalence declined by 0.9% per
annum during the pre-SCC period (Table 1, Figure 1) and by 4.1%
annually during the SCC period (from 519 per 100 000 to 276 per
100 000), with an overall decline of 2.5% per annum prior to
DOTS implementation (95% CI: 1.1–3.8%). After DOTS imple-
mentation, the rate of decline accelerated to 5.6% per annum,
with prevalence declining to 239 per 100 000 in 2001–2003.
The decline during the DOTS period was similar in males and
females for both culture-positive (10.9 vs 12.3%, respectively)
and smear-positive cases (4.7 vs 3.2%, respectively).
For the entire pre-DOTS period, including both pre-SCC and
SCC periods, the annual rates of decline in culture-positive and
smear-positive tuberculosis were 2.3 and 2.5%, respectively. In
the DOTS period, the annual rate of decline of culture-positive
tuberculosis increased to 11.9% (from 510 to 372 per 100 000)
and for smear-positive tuberculosis to 5.6% (from 276 to 239
per 100 000).
Considering all cases identified by both symptom and
radiographic screening, the annual decline observed for
culture-positive tuberculosis was 1.4% (from 1039 to 827 per
100 000 population) during the pre-SCC period, 2.1% during
the SCC period (from 827 to 608 per 100 000), and 11.3%
(from 608 to 450 per 100 000) during the DOTS period. The
corresponding annual declines for smear-positive tuberculosis
were: pre-SCC: 0% (646–636 per 100 000); SCC: 4.3%
(636–328 per 100 000); and DOTS: 9.0% (328–259 per 100 000).
Restricting the analysis to the 53 sampled clusters (of the
78 total), which were surveyed during both the DOTS and
the pre-DOTS periods, very similar decreases in rates were
observed.
A multivariate linear regression analysis of the data with
time, rifampicin (short-course chemotherapy), and DOTS as
dummy variables showed that the annual decrease in preval-
ence of culture-positive tuberculosis over time was 2.1% (95%
CI: 1.1–3.2%), short-course chemotherapy was associated with
an additional 1.5% annual decrease in prevalence (95% CI:
9.7 to 11.5%), and DOTS was associated with an additional
10.0% annual decrease (95% CI: 2.8–16.6%).
For the entire community, the absolute decrease in preval-
ence over the 33 years was 645 per 100 000 for culture-positive
tuberculosis (i.e. from 1017 to 372 per 100 000). Of the
decrease, 21% occurred after just 2.5 years after implementa-
tion of DOTS, as against the 8% (2.5/33 years) that would have
occurred if the decrease over time had been uniform.
During the period of DOTS implementation, a decreasing
proportion of cases was diagnosed through active disease
survey and an increasing proportion through the routine
diagnostic and treatment system. The proportion detected
through community surveys decreased from 18.8% in 2000
and 2001, the first 2 full years of DOTS implementation, to
8.1% in 2002 and 2003 (379 of 2011 vs 159 of 1969, P ,
0.00001); similar trends were seen among both new and
re-treatment patients.
Discussion
We have demonstrated a substantial annual decline in the
prevalence of culture-positive (11.9%) and smear-positive
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Figure 1 Trends in prevalence of culture-positive (C1) and
smear-positive (S1) tuberculosis in South India, 1968–2001. Age–sex
standardized with reference to 1968–1970 survey population
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(5.6%) pulmonary tuberculosis cases after introduction of the
DOTS strategy. In the survey area, we were able to measure the
association of tuberculosis prevalence with tuberculosis control
programmes in various periods (i.e. pre-SCC and SCC, which
together constitute the pre-DOTS period, and the DOTS
period). We observed the same annual decline in culture-
positive tuberculosis (2.1%) during the pre-SCC and SCC
periods; however, the decline became far more rapid after
implementation of the DOTS strategy (11.9%). Similarly, this
project recently documented a significant decline in tubercu-
losis infection during the DOTS period after no significant
decrease during either the pre-SCC or SCC periods.
15
The 5.8%
decline in annual risk of tuberculosis infection documented
15
was similar to the 5.6% decrease in smear-positive prevalence
reported here. The prevalence of smear-positive tuberculosis
should, on a theoretical basis, correlate well with annual risk of
infection, since most infections are spread by smear-positive
prevalent cases.
Use of rifampicin-containing SCC regimens appears to have
been associated with a slight hastening of the long-term
gradual decline in tuberculosis prevalence in this area.
However, only when DOTS was implemented did a rapid
decrease in tuberculosis prevalence occur. Thus, changing
recommended drug regimens alone does not appear to
adequately control tuberculosis. It is essential that there be a
management system in place to ensure that patients take
medication regularly. The importance of direct observation of
treatment has been emphasized by the Tuberculosis Research
Centre for nearly 50 years.
16
The rapid increase in the proportion of cases identified
through the diagnostic and treatment system in this area, from
81% during the first 2 years of DOTS implementation to 92%
in the next 2 years, is encouraging. This provides evidence to
support what has been described as a ‘recruitment effect’ of
good quality care, whereby improved treatment systems draw
patients into the system of care.
17
In addition to recognition
on the part of patients that the programme was reliably
curing those in care, the increased case detection through the
DOTS programme may also reflect rational economic decisions
of patients. Cost per patient in the study area dropped by
more than two-thirds after DOTS was implemented, from
Rs 4588 (~US $109) before DOTS was implemented to Rs 1398
(~US $32).
18
In addition, this finding suggests that monitoring
disease trends by monitoring case notifications may, in the
presence of an effective control programme with a good
notification system, provide a reasonable approximation of the
epidemiology of tuberculosis in an area.
Comparison with other studies
Although our analysis is, to our knowledge, the first to employ
systematic community disease surveys to monitor the impact of
the WHO-recommended DOTS strategy, several systematic
surveys have documented declines in tuberculosis case rates in
the context of sound diagnosis and treatment. In Kolı´n, former
Czechoslovakia, prior to establishment of the global DOTS
strategy, an intensive surveillance and treatment programme
employing direct observation of anti-tuberculosis treatment in
a population of 100 000 reduced the prevalence of bacteriolo-
gically (smear or culture) confirmed tuberculosis by 10%
annually, from 150 per 100 000 in 1960 to 91 per 100 000 in
1964; however, no historical comparison data were available.
5
In Korea, nationwide prevalence surveys between 1965 and
1995 found a 5% annual decline in bacteriologically confirmed
cases (from 940 per 100 000 in 1965 to 219 in 1995).
4
Investigators in Beijing, China, reported an annual decline of
17.2% (from 127 per 100 000 in 1979 to 16 per 100 000 in
1990) in prevalence of smear-positive pulmonary tuberculosis
based on results for Beijing of three nationwide tuberculosis
prevalence surveys conducted in 1979, 1984–1985, and 1990.
19
A strategy similar to DOTS was implemented in Beijing in 1978,
and the decline was attributed to the increase in programme
coverage from 10% in 1978 to 90% in 1990. As their
community survey methods are not fully described, it is not
possible to make detailed comparisons. The annual decline
reported was nearly twice the 9.0% observed in our area,
although in the first 5.5 years of their implementation the
annual rate of decline was lower (13.8%) than in the last
5.5 years (20.4%). The fact that our programme did not meet
the global target of 85% treatment success (77% treatment
success in our area vs the >85% global target and .90%
success in Beijing) probably resulted in less than the full
potential impact of DOTS implementation. Direct observation
in the continuation phase is once-weekly in the programme
in India. In addition, our baseline survey overlapped with
initial DOTS implementation, which could result in an
underestimation of the impact of DOTS.
Other reports on the impact of DOTS on tuberculosis have
been based on case notification.
20,21
Thus, Peru had reported
a decline of ~6% per year during 1993–2000, following a
stationary phase up to 1991 and an increase between 1991 and
1993 owing to improved case detection after DOTS imple-
mentation.
20
The decline was observed even though case
detection efforts increased and was attributed to successful
implementation of the DOTS strategy. New York City reported
that cases of tuberculosis tripled between 1978 and 1992, then
declined 9.3% annually through 1994 among culture-positive
pulmonary tuberculosis cases notified, despite the presence of
HIV.
22
This decrease was attributed to improved tuberculosis
control, including standardization of short-course treatment,
direct observation of treatment, systematic monitoring of all
treatment outcomes, and reduction of nosocomial spread of
tuberculosis among HIV-infected persons. The rate of decline
observed in these two reports was similar to what we obtained
in our area based on community survey.
Limitations
A limitation of our study is that we estimated the rate of
decline during the DOTS period from the findings of two
surveys only. However, the surveys were based on random
sampling and the magnitude of the decline is substantially
greater than the decline that occurred in the previous 3 decades.
Because survey participation was high, it is unlikely that there
were either selection or surveyor bias. Another limitation is
that we assessed the impact of DOTS by comparing the decrease
in prevalence with temporal changes in the past in the same
population. While it would have been ideal to compare it with
the changes in a similar area without DOTS over the same
period, this was not ethically feasible as DOTS had been
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designated the national policy of care for tuberculosis. We have
also not considered socioeconomic changes in the community
due to non-availability of accurate information; there have
been, however, no apparent significant socioeconomic changes
in the years covered by the survey. Our study may have
over-estimated the impact of SCC and under-estimated the
impact of DOTS; this is because the baseline survey, which
lasted for 2.5 years, was begun at around the same time DOTS
implementation began and could, consequently, have yielded a
lowered prevalence due to the impact of DOTS. Finally, our
findings are not generalizable to areas of the developing
world with a high prevalence of HIV infection, as ,1% of
tuberculosis patients in the survey area were infected with HIV
(Tuberculosis Research Centre, unpublished data), or to areas
with high prevalence of rifampicin-resistant tuberculosis strain;
rifampicin resistance in previously untreated patients in this
area was ,2%.23
Conclusion
Implementation of DOTS enables effective clinical and
public health management and resulted in a much more
rapid decline in culture-positive tuberculosis prevalence
than the decline that occurred in this area for more than
30 years previously. These results suggest that, in the
absence of a large epidemic of HIV and with relatively low
levels of rifampicin resistance, DOTS can result in rapid
control of tuberculosis as measured through a sharp decline
in prevalence and a significant reduction in the annual risk
of tuberculosis infection.
15
Future surveys will determine the
long-term impact on tuberculosis prevalence and the effect on
incidence.
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KEY MESSAGES
 Anti-tuberculosis treatment without the management package known as DOTS does not adequately control
tuberculosis, even in the absence of a high prevalence of HIV infection or anti-tuberculosis drug resistance.
 DOTS appears to result in rapid reduction of tuberculosis prevalence in areas without a large HIV epidemic and
with relatively low levels of rifampicin resistance.
 Implementation of DOTS increases the proportion of patients who present to governmental health care facilities.
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